Medicare GLP-1 Bridge July 2026: $50 Copay Rules for FEHB Retirees | Fed Pilot
On May 6, 2026, the Centers for Medicare & Medicaid Services announced a new short-term demonstration called the Medicare GLP-1 Bridge. Starting July 1, 2026 — about five weeks from now — Medicare beneficiaries who are clinically eligible can pay a flat $50 monthly copay for certain weight-loss GLP-1 medications. For federal retirees who carry FEHB alongside Medicare Part D, this looks like a windfall on paper. But there is a catch buried in the program design that every federal retiree planning to use it needs to understand before signing up.
The short answer: Starting July 1, 2026, eligible Medicare beneficiaries can access Wegovy, Foundayo, or Zepbound KwikPen for a flat $50 monthly copay through the two-year Medicare GLP-1 Bridge demonstration. The critical catch for FEHB retirees: that $50 does not count toward the 2026 Part D $2,100 out-of-pocket cap, and the program ends December 31, 2027.
Key Takeaways
- The Bridge runs July 1, 2026 – December 31, 2027 only — a two-year demonstration, not a permanent benefit.
- Eligible drugs: Wegovy (all formulations), Foundayo (all formulations), Zepbound KwikPen ONLY — single-dose vials are excluded.
- The $50 copay does NOT count toward the 2026 Medicare Part D out-of-pocket cap of $2,100; you still owe up to $2,100 separately on other covered drugs.
- FEHB EGWPs (employer/union group waiver plans) are eligible to participate, but participation is plan-by-plan — call your plan to confirm before July 1.
- Clinical BMI documentation at therapy initiation is required; federal retirees already on a GLP-1 who have lost weight still qualify if their starting BMI met the threshold.
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a two-year demonstration project — not a permanent benefit. It runs from July 1, 2026 through December 31, 2027. CMS designed it as a bridge while the agency continues to study whether anti-obesity medications should be covered under standard Part D going forward.
During those eighteen months, eligible Medicare beneficiaries can fill prescriptions for three specific anti-obesity GLP-1 medications at a flat $50 copay per monthly supply: Wegovy (semaglutide, all approved formulations including oral tablet), Foundayo (all approved formulations), and Zepbound (tirzepatide) KwikPen formulation only. Standard single-dose vials and pens are not covered by the Bridge.
CMS pays the manufacturer a negotiated net price (roughly $245 per monthly supply) and the beneficiary pays the fixed $50 difference. Manufacturer coupons cannot be applied on top of the $50, and low-income subsidies do not reduce it further.
Who Is Eligible for the Medicare GLP-1 Bridge?
Eligibility requires three conditions: (1) enrollment in a Medicare Part D plan or an EGWP that has elected to participate, (2) a qualifying body-mass index documented at the time drug therapy was initiated, and (3) prior authorization from the prescribing physician.
The clinical criteria: a BMI of 35 or higher, or a BMI of 30+ with one qualifying comorbidity, or a BMI of 27+ with two qualifying comorbidities. The BMI threshold must have been documented at the start of therapy — not at the moment of the prior-authorization request. Federal retirees already on a GLP-1 for a year who have since lost weight still qualify if their starting BMI met the threshold. Humana administers the Bridge through the same infrastructure CMS uses for the LI NET program.
Why Don’t the $50 Copays Count Toward the Part D Out-of-Pocket Cap?
The 2026 Medicare Part D out-of-pocket maximum is $2,100. Once a beneficiary hits that cap, the federal government covers their drug costs for the remainder of the year — one of the most consequential improvements in recent Medicare history.
The $50 Bridge copays do not count toward that $2,100 cap. CMS designed the Bridge to operate outside the normal Part D benefit, which means none of the $600/year you’ll pay in Bridge copays counts as “true out-of-pocket” spending under Part D rules. If you take other expensive medications, you still have to spend $2,100 separately on those drugs before catastrophic coverage kicks in.
This is the same kind of structural quirk that complicates the Medicare and FEHB coordination decision, and it matters most for retirees already managing chronic-condition prescription costs alongside FEHB premiums.
How Does the Medicare GLP-1 Bridge Interact With FEHB?
If you are a federal retiree enrolled in FEHB plus Medicare Part B, you may already be enrolled in your FEHB plan’s Part D EGWP — most major FEHB plans, including BCBS FEP and GEHA Standard, offer integrated EGWPs at no additional premium for Medicare-eligible enrollees. EGWPs are eligible to participate in the Bridge, but participation is decided plan-by-plan.
Practical action item: before July 1, call your FEHB plan and confirm (1) that the plan’s Part D EGWP is participating in the Bridge demonstration, and (2) that they understand the prior-authorization mechanics specific to the Bridge, which differ from their normal anti-obesity drug PA process.
The relationship between your FEHB premium in retirement and Medicare costs already takes some untangling. The Bridge adds a new line item on top — separate from your FEHB premium, separate from your Part B premium, separate from your normal Part D copays.
Does the GLP-1 Bridge Create an IRMAA Risk for High-Income Retirees?
Federal retirees with modified adjusted gross income above the 2026 IRMAA thresholds — $109,000 for individuals or $218,000 for joint filers — pay income-related surcharges on both Part B and Part D. The 2026 standard Part B premium is $202.90; the first IRMAA tier adds $81.20 for individuals earning $109,001–$137,000. The Part D IRMAA surcharge starts at $14.50 monthly at the same income tier.
The Bridge’s $50 copay does not shield you from IRMAA. If you fill twelve months of Bridge prescriptions, that’s $600 spent, but none of it changes your IRMAA status — IRMAA is calculated from your tax return, not your drug spending. Federal retirees doing strategic Roth conversions or large TSP withdrawals should weigh whether using the Bridge is worth crossing an IRMAA threshold.
What Should FEHB Retirees Do Before July 1 to Use the GLP-1 Bridge?
- Document your starting BMI now. Get a clinical visit on record with current weight, height, and BMI calculation. The Bridge requires the BMI threshold to have been met at therapy initiation.
- Confirm your FEHB plan’s EGWP is participating. Call member services; get written or emailed confirmation if possible.
- Discuss comorbidity documentation with your physician. If your BMI is between 27 and 35, qualifying comorbidities (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, cardiovascular disease) must be documented at prior authorization.
- Decide on the formulation before the appointment. If you want Zepbound, your prescription must specify the KwikPen formulation. Single-dose vials are not covered. Wegovy and Foundayo have no formulation restriction.
- Plan for the December 31, 2027 sunset. If you start a GLP-1 in mid-2026, you need a plan for what your drug cost looks like after the program ends — which depends on whether your FEHB plan covers anti-obesity GLP-1s under its regular Part D benefit going forward.
What Happens After the Bridge Ends December 31, 2027?
The Bridge is a demonstration. Unless CMS extends it, the $50 copay disappears at the end of 2027. OPM has already directed FEHB carriers to expand GLP-1 coverage for plan year 2027 with new prior-authorization and well-care attestation requirements, which we covered in our 2027 FEHB Changes piece. After December 31, 2027, GLP-1 access for federal retirees depends on what CMS decides about permanent Part D coverage and what your specific FEHB plan offers.
For now, the Bridge is the cheapest path to a GLP-1 anti-obesity drug for an eligible Medicare beneficiary in 2026 and 2027 — provided you understand that the $600/year you’ll spend on copays buys clinical access but no progress toward your Part D out-of-pocket cap.
Frequently Asked Questions
What happens to my GLP-1 coverage after December 31, 2027?
The $50 Bridge copay ends. Coverage going forward depends on your FEHB plan’s regular Part D benefit and any permanent Medicare coverage CMS establishes. Plan for a potential coverage gap unless CMS extends the program.
Can I use the Bridge if I have Medicare Part B but not Part D?
No. The Bridge requires a Medicare Part D plan or a participating EGWP. Part B alone does not provide Part D drug coverage.
Does the $50 copay change if I’m subject to IRMAA?
No. The Bridge copay is flat $50 regardless of income. IRMAA surcharges apply to your Part B and Part D premiums, not to the Bridge copay itself.
Is prior authorization required only once, or does it need to be renewed?
CMS Bridge guidance requires prior authorization at therapy initiation. Re-authorization requirements for continued treatment depend on your individual plan — confirm with your FEHB plan’s pharmacy benefit manager before assuming authorization auto-renews.
Can manufacturer coupons reduce the $50 copay further?
No. CMS explicitly prohibits manufacturer coupon stacking on Bridge copays. The $50 is the final consumer cost — no commercial discounts apply.
I’m not yet on Medicare but will enroll in July 2026 — can I immediately use the Bridge?
Yes, as long as your Medicare Part D coverage is active by your first fill date and your FEHB plan’s EGWP is participating.
Decisions like the GLP-1 Bridge interact with FEHB premiums, IRMAA thresholds, TSP withdrawal timing, and Part B enrollment in ways that aren’t obvious until you see them laid out together. Our free Fed Pilot workshop walks through how FEHB, Medicare, and your federal pension fit together — and where the financial tripwires hide.
